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Abstract
The discovery of microRNAs (miRNAs) added an extra level of intricacy to the already complex
system regulating gene expression. These single-stranded RNA molecules, 18–25 nucleotides in
length, negatively regulate gene expression through translational inhibition or mRNA cleavage. The
discovery that aberrant expression of specific miRNAs contributes to human disease has fueled
much interest in profiling the expression of these molecules. Real-time quantitative PCR (RQ-PCR)
is a sensitive and reproducible gene expression quantitation technique which is now being used to
profile miRNA expression in cells and tissues. To correct for systematic variables such as amount
of starting template, RNA quality and enzymatic efficiencies, RQ-PCR data is commonly normalised
to an endogenous control (EC) gene, which ideally, is stably-expressed across the test sample set.
A universal endogenous control suitable for every tissue type, treatment and disease stage has not
been identified and is unlikely to exist, so, to avoid introducing further error in the quantification
of expression data it is necessary that candidate ECs be validated in the samples of interest. While
ECs have been validated for quantification of mRNA expression in various experimental settings,
to date there is no report of the validation of miRNA ECs for expression profiling in breast tissue.
In this study, the expression of five miRNA genes (let-7a, miR-10b, miR-16, miR-21 and miR-26b) and
three small nucleolar RNA genes (RNU19, RNU48 and Z30) was examined across malignant, benign
and normal breast tissues to determine the most appropriate normalisation strategy. This is the
first study to identify reliable ECs for analysis of miRNA by RQ-PCR in human breast tissue.
Background
Approximately 98% of the human transcriptome is non-
protein-coding RNA (ncRNA) [1,2]. The fraction of
ncRNA believed to be functional in cells was once limited
to the well-characterised transfer and ribosomal RNAs.
However, this fraction has recently been expanded to
include microRNAs (miRNAs), a class of short, single-
stranded RNAs that target, through nucleotide comple-
mentarity, specific messenger RNAs, enabling them to
negatively modulate gene expression. First characterised
in 1993, miRNAs were initially shown to be involved in
the control of developmental timing in Caenhorhabditis
elegans [3]. Now, 15 years later, 541 human miRNAs have
been submitted to the most recent edition of the online
miRNA sequence repository, miRBase [4,5]. A very small
proportion of identified miRNAs have verified roles, in
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processes such as cell proliferation [6] and apoptosis [7].
It may be some time before the full catalogue of biologi-
cally-functional miRNAs is compiled but the involvement
of miRNAs in the regulation of cancer-related genes at the
post-transcriptional level has already led to miRNAs being
hailed as a novel class of tumour suppressor genes and
oncogenes and the coining of the term "oncomiR"
[reviewed in [8] and [9]]. Further elucidating our limited
understanding of the mechanisms of metastasis [10,11];
the spread of cancer cells from the primary neoplasm to
distant organs, has become a major focus in miRNA stud-
ies [12-14]. Gene signatures from these studies will con-
tribute to our understanding of the multi-step processes of
metastasis and may also enable advanced indication of
the likelihood of tumour invasion and metastasis based
on the characteristics of the primary tumour.
The expression of miRNAs has been studied using tradi-
tional, semi-quantitative methods such as northern blot-
ting [15], bead-based flow-cytometry [16] and microarray
technology [17]. However, by far the method of choice for
expression quantitation is real-time quantitative PCR
(RQ-PCR) due to its sensitivity, wide dynamic range and
low template requirements. The technique has itself been
revolutionised in recent years with the development of
stem-loop primers that specifically convert the mature,
functional miRNA into its DNA complement [18]. Fur-
thermore, a multiplex stem-loop RQ-PCR format is cur-
rently being refined to allow multiple miRNAs to be
transcribed simultaneously [19,20].
To produce reliable relative RQ-PCR data, corrections
must be made for variation between reactions introduced
during the steps from sample preparation to amplifica-
tion. Incorporating an endogenous control (EC) gene into
the experimental design is an effective method of normal-
ising the data but candidate ECs must be tested on a rep-
resentative number of the sample population if not the
entire sample set [21-23]. Use of an unreliable EC may
lead to inaccurate, unreliable results and previous studies
show that mRNA expression can be made to appear up- or
down-regulated by one order of magnitude based solely
on the choice of EC [21].
Using the Medical Subject Heading (MeSH) terms micro-
RNAs, neoplasm and reverse transcriptase polymerase
chain reaction, a recent PubMed search returned 42 arti-
cles, 5 of which detailed miRNA RQ-PCR expression pro-
filing studies using human neoplastic breast samples. The
EC(s) used in these studies were let-7a and miR-16 [24],
U6 small nuclear RNA (snRNA) and tRNA for initiator
methionine [25], 18S rRNA [26], glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) [27] and in one article,
the EC used for RQ-PCR analysis was not given [28]. There
is currently no consensus on suitable ECs for quantitative
analysis of miRNA by RQ-PCR in human breast tissue.
Concern has been expressed regarding the use of ribos-
omal RNAs in normalisation strategies as they can be
expressed at much greater levels than the target RNA mak-
ing it very difficult to quantify an rRNA and a rare tran-
script in the same RNA dilution [22,29,30]. Moreover,
there is evidence of rRNA deregulation in apoptosis [31].
It is also clear that the traditionally-used but seldom vali-
dated GAPDH and β-actin (ABTB) genes are not suitable
endogenous controls for some studies [32-34]. Our aim
was to identify from a panel of RNA species similar to
miRNAs, suitable EC candidates for miRNA analysis by
RQ-PCR.
The expression of eight small RNAs was determined in 36
fresh-frozen breast tissues; three small nucleolar RNAs
(snoRNAs, RNU19, RNU48 and Z30) and five miRNAs
(let-7a, miR-10b, miR-16, miR-21 and miR-26b). The five
miRNAs were chosen as candidate ECs for this study based
on their known expression in human breast tissue and/or
their previous use as an EC gene for miRNA RQ-PCR anal-
ysis [24]. The three snoRNA genes were selected from a
panel of ten commercially available TaqMan control
assays. SnoRNAs, found within the nucleolus, range from
60–300 nt in length and chemically modify rRNA [35],
small nuclear RNA (snRNA) [36] and mRNA [37] through
their recognition of short sequences in the target molecule
and recruitment of associated proteins to the site. MiR-
30*, previously referred to as miR-30a-3p, targets RNA
involved in several cancer-related biological processes
[38] and was chosen as a target gene to investigate the
effect of EC gene selection on relative quantitation.
Downregulation of miR-30* has previously been shown
to increase transcription of mRNAs involved in processes
such as angiogenesis (thrombospondin I, cysteine-rich,
angiogenic inducer) and cell cycle transition (cyclin-
dependent kinase 6) [38]. Samples consisted of malignant
(n = 21), benign (n = 5) and normal (n = 5) breast tissues.
Malignant tumour tissues were representative of all
tumour grades and hormone receptor states. The malig-
nant breast tumour tissues were divided into three groups
depending on the patient's disease progression in the five
years following removal of the primary tumour; tumours
from patients who did not develop metastases (metas-
tases-free, MF, n = 13), those from patients who devel-
oped bone metastases (BM, n = 7) and those from patients
who developed visceral and bone metastases (VBM, n =
6).
Results
RNA analysis
Concentrations of small RNA ranged from 45–431 ng μL-
1. The distribution of miRNA yields (RNA in the 10–35 nt
range) across the various malignant groups, benign and
normal tissues was determined using the Agilent SmallBMC Molecular Biology 2008, 9:76 http://www.biomedcentral.com/1471-2199/9/76
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RNA Assay (Table 1). Percentage of miRNA in the small
RNA fraction ranged from 12%–98%. For the majority of
samples, miRNA comprised 26–75% of total small RNA.
High miRNA yields (> 75% miRNA) were seen in samples
from the BM and MF groups. Low yields (< 25% miRNA)
were seen in all groups apart from the normal tissue
group. The large RNA samples, extracted separately but at
the same time as the small RNA used for this study, all had
an RNA integrity number (RIN) ≥ 7.
Relative Expression Quantitation
The threshold cycle (Ct) is the amplification cycle number
at which the fluorescence generated within a reaction rises
above a defined threshold fluorescence [39]. The eight
candidate ECs displayed a wide expression range with Ct
values between 18 and 36. MiR-16 and miR-21 showed
relatively high expression with median Cts of 21, while
let-7a, miR-10b, miR-26b and RNU48 were moderately
abundant with median Cts of between 23 and 27. Z30 had
lower abundance with a median Ct of 29. RNU19 expres-
sion was very low in these samples with Cts ranging from
26.2 to 38.9. It was decided to exclude RNU19 from fur-
ther analysis due to its low expression. Ct values were con-
verted to relative quantities (Q.Rel) using the formula: E-
ΔCt, where E = PCR amplification efficiency and ΔCt = aver-
age Ct, test sample-average Ct, calibrator sample. There
was no significant difference in variance between genes (P
> 0.05, Fig. 1B). The relative quantities did not differ sig-
nificantly between the MF, BM, VBM and BEN groups for
any of the candidate ECs (P > 0.05; Fig. 1A). As
NormFinder and geNorm assume candidates are not dif-
ferentially expressed between groups, this analysis is nec-
essary to validate use of these methodologies [40].
Equivalent expression between the tumour tissues
(benign and malignant) and the normal breast tissues
(used as the calibrator) was confirmed for each of the
seven candidate ECs using the equivalence test and a fold
change cut-off of 3[41]. All genes, with the exception of
Z30, were also equivalently expressed between the malig-
nant and benign tumour groups using a fold change cut-
off of 3.
Stability Candidate EC Expression
Stability of the candidate ECs was examined using
geNorm and NormFinder. The ranking of the candidates,
as determined by these programmes, is shown in Table 2.
The lower the stability value, the higher the gene stability.
With a stability value of 0.312, NormFinder selected let-7a
as the most stably expressed single gene. The best combi-
nation of two genes, let-7a and RNU48, further reduced
the NormFinder stability value to 0.221. Two out of the
seven genes showed geNorm stability measures (M)
below the default limit of 1.5 and the programme identi-
fied let-7a and miR-16 as the most stable pair of ECs (M =
0.978).
Effect of EC on Relative Quantity of miR-30*
To assess the effect of EC on relative quantitation of the
target gene, miR-30*, this miRNA was normalised using
each of the candidate EC genes in turn. Depending on the
normaliser, miR-30* expression was either significantly
different between tissue groups (P < 0.05) or no differ-
ences were detected. When normalised using miR-26b,
ranked in the top four mosts Table 3 andidates by both
geNorm and NormFinder (Table 2), no differences were
detected between tissue groups. Normalisation to all
other individual ECs detected significant differences
between the BM and VBM tissue groups. Only normalisa-
tion with RNU48 detected a significant difference in miR-
30* expression between the MF and VBM tissue groups.
GeNorm selected let-7a and miR-16 as the most stable EC
pair and let-7a was selected as the single most stable EC
gene using NormFinder. Thus the effect of using either let-
7a as a single gene or using the recommended EC pair, let-
7a and miR-16, on miR-30* expression was assessed. Sig-
nificant differences in miR-30* expression were detected
between tissue groups using either the one EC (P = 0.007)
or the two EC (P = 0.01) approach, however the BM and
MF tissue groups were found to be significantly different
using the EC pair, let-7a and miR-16 but this was not
detected when let-7a was used as the sole EC gene. The
lowest pairwise variation value (V) was generated using
the top five genes from the panel, indicating that this
Table 1: miRNA yield from small RNA-enriched fractions according to tissue group
Tissue group\Percentage of miRNA in small RNA-enriched fraction 1–25% 26–50% 51–75% 76–100%
MF 34 3 3
BM 11 2 3
VBM 15 0 0
BEN 12 2 0
Normal 01 4 0
Total 61 31 1 6
Extracted RNA, enriched for small RNA, was analysed using the Agilent Small RNA Assay. The percentage of miRNA (10–35 nt) in each small RNA-
enriched sample (< 200 nt) was determined.
Abbreviations: MF = metastases free, BM = bone metastases, VBM = visceral and bone metstases, BEN = benign.BMC Molecular Biology 2008, 9:76 http://www.biomedcentral.com/1471-2199/9/76
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would be the most stable EC gene set to use. MiR-30* was
normalised using the top two EC genes and using the top
five EC genes to assess what effect this would have on
miR-30* relative quantification. Significant differences in
miR-30* expression were detected between the tissue
groups using either the top two ECs (P = 0.01) or the top
five ECs (P = 0.002, Fig. 2B), however the post-hoc analyses
varied slightly in that the two gene normalisation detected
a difference between the BEN and MF tissue groups not
detected by the five EC gene approach. Conversely, the 5
gene approach identified a significant difference in miR-
30* expression between the MF and VBM tissues, not
detected when using the most stable pair. Both normalisa-
tion strategies did detect significant differences between
the BM vs MF groups, the BM vs VBM groups and the BEN
vs VBM groups.
Discussion
In recent years, miRNAs have emerged as key players in
tightly-controlled biological processes such as prolifera-
tion [6], apoptosis [7,42] and tumour invasion [13]. MiR-
NAs, first implicated in malignancy in 2002 [43], are
known to be deregulated and/or mutated in numerous
cancers including breast cancer [44] and there is evidence
to suggest that miRNA expression profiles may be more
accurate in classifying breast cancer subtypes than mRNA
expression profiles [16].
Adaptation of traditional RNA isolation and reverse tran-
scription protocols has facilitated the application of RQ-
PCR to the study of miRNA expression. Mature miRNAs
were amplified and quantified using PCR for the first time
in 2005 [18,45] and recent developments include a 220-
plex RQ-PCR allowing the analysis of multiple miRNAs
from single cells [19]. The high sensitivity of RQ-PCR
demands appropriate normalisation to correct for non-
biological variation and the use of EC genes remains the
most commonly used method. The issue of carefully
selecting and validating EC genes has already been dis-
cussed for a number of experimental systems in the con-
text of RQ-PCR for mRNA [21,29,46] however, this issue
has not yet been addressed in relation to the relative quan-
titation of miRNA in breast tissue. This issue is particularly
pertinent to the area of miRNA studies utilising RQ-PCR
since it is still common practice to synthesise a gene-spe-
cific cDNA for each sample, using miRNA-specific prim-
ers, thereby introducing additional non-biological
variation not accrued during the synthesis of cDNA from
mRNA when using random or oligo-dT primers.
This paper describes the first systematic assessment of can-
didate ECs for the normalisation of miRNA RQ-PCR data
in breast cancer. In the rapidly evolving field of miRNA
reasearch, consensus has not yet been reached on how
best to tackle this issue. Numerous RNA species, including
rRNAs, tRNAs, snRNAs and miRNAs have previously been
used as ECs in miRNA RQ-PCR studies of the breast. Con-
cern has been expressed regarding the use of rRNAs in nor-
malisation strategies as they can be expressed at much
greater levels than the target RNA making it very difficult
to quantify a rRNA and a rare transcript in the same RNA
dilution [22,29,30]. Moreover, a role for rRNA in apopto-
sis [31] and cancer [47] has been reported. A proportion
of snRNAs and snoRNAs may exhibit tissue-specific and
developmental regulation [48] emphasising the need for
validation of commercially-available control assays. U6
snRNA (RNU6B), commonly used to normalise miRNA
RQ-PCR data [49,50] was found to be less stably
Relative quantity of each candidate EC Figure 1
Relative quantity of each candidate EC. (A) Quantity 
of the candidate endogenous control genes let-7a, miR-10b, 
miR-21, miR-16, miR-26b, RNU48 and Z30, relative to cali-
brator (normal tissues) and corrected for amplification effi-
ciency (Q. rel = E-ΔCt), in the benign (BEN, clear ), bone 
metastases (BM, dark), metastases free (MF, dashed) and vis-
ceral and bone metastases (VBM, shaded) groups. The boxes 
show the interquartile range and median, whiskers indicate 
the range and outliers are depicted with the symbol (*). No 
difference was found within gene between the tissue sub-
groups (P>0.05) thus establishing the validity of EC compari-
son. (B) Variation associated with candidate endogenous 
control genes. Relative quantity of each gene is relative to 
calibrator (normal tissues) and corrected for amplification 
efficiency (Q.rel = E-ΔCt). There was no significant difference 
in variance associated with relative gene expression (P > 
0.05).
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expressed than let-7a and miR-16, the EC pair proposed
by this study [51].
This is the first report detailing the percentage of miRNA
retrieved in small RNA-enriched fractions of primary
breast tissue. RNAs detected using the Agilent small RNA
assay include miRNAs, smaller ribosomal RNAs such as
the 5.85S (154 nt) and 5S (117 nt) subunits, transfer
RNAs (73–93 nt) and snoRNAs (60–300 nt). Perhaps
unsurprisingly, we found the proportion of miRNA in the
Table 2: Ranking of candidate EC gene and choice of best pair of EC genes by NormFinder and geNorm programmes
Rank NormFindera geNormb
Gene Stability Gene Stability (M)
1 let-7a 0.312 let-7a 1.427
2 miR-16 0.379 miR-16 1.473
3 RNU48 0.401 miR-26b 1.538
4 miR-26b 0.425 RNU48 1.567
5 miR-10b 0.435 miR-10b 1.667
6 miR-21 0.601 miR-21 1.692
7 Z30 0.624 Z30 2.272
Best combination let-7a/RNU48 0.221 let-7a/miR-16 0.978
Greater expression stability is indicated by a lower stability value (M). Results for seven EC candidates are given as RNU19 was excluded from 
analysis due to its low expression in the breast tissues. For NormFinder analysis, breast tissue samples were grouped into metastases-free (MF), 
bone metastases (BM), visceral and bone metastases (VBM) and benign (BEN). The stability is calculated from the intra- and inter-group variation 
and the best combination of EC genes is also given. b GeNorm stability is based on an estimate of the pairwise variation (M).
Table 3: Clinical and pathological data on malignant tumour samples where available
Patient
Number
Patient
Age
Menopausal
status
Size
(mm)
TNMG r a d e E RP RH E R 2 /
neu
Subtype Metastatic
grouping
1 41 Pre 25 2 0 0 P Luminal A/B MF
2 50 Pre 35 2 1 0 1 P P N Luminal A MF
3 38 Post 35 2 1 0 1 P P N Luminal A MF
4 43 Pre 10 1 0 0 1 P P N Luminal A MF
5 49 Post 20 1 1 0 2 P N N Luminal A MF
6 78 Post 20 1 1 0 1 P P N Luminal A MF
7 51 Post 18 1 0 0 N N LuminalA/Basal MF
8 75 Post 36 4 1 0 2 P Luminal A/B MF
9 59 Post 50 2 1 0 3 P P N Luminal A BM
10 53 Post 85 3 1 0 3 N N N Basal MF
11 43 Pre 50 2 1 0 3 P N N Luminal A MF
12 69 Post 35 4 2 0 3 P P N Luminal A VBM
13 66 Post 12 1 0 0 3 P N N Luminal A MF
14 58 Post 20 4 1 0 2 P P N Luminal A MF
15 58 Post 15 1 1 0 2 P P N Luminal A VBM
16 70 Post 20 1 0 0 2 P P N Luminal A MF
17 52 Post 25 4 1 0 3 P P P Luminal B VBM
18 78 Post 1 0 0 P P N Luminal A BM
19 61 Post 33 2 1 0 1 P P P Luminal B BM
20 48 Pre 30 2 1 0 3 P P N Luminal A VBM
21 50 Pre 30 2 1 0 3 N N Basal/HER-2 VBM
22 51 Post 20 1 0 1 P Luminal A/B VBM
23 69 Post 40 2 1 0 2 P N N Luminal A BM
24 58 Post 21 4 0 3 N N P HER-2 BM
25 61 Post 35 2 1 0 3 P P N Luminal A BM
26 64 Post 15 1 1 0 2 P N P Luminal B BM
T, N and M refer to the primary tumor size, nodal status and distant metastases status according to the TNM breast cancer classification system. 
ER: = oestrogen receptor status; PR: = progesterone receptor status and HER2/neu = v-erb-b2 erythroblastic leukaemia viral oncogene status. 
Where data was not available for ER, PR and HER-2, possible subtype based on available hormone receptor status is given. Metastatic groupings 
refer to patient status five years after presentation; patients were either metastases-free (MF), had developed bone metastases (BM) or had 
developed visceral and bone metastases (VBM).BMC Molecular Biology 2008, 9:76 http://www.biomedcentral.com/1471-2199/9/76
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small RNA sample ranged from 12–98%. The varying
miRNA yields were well distributed amongst the tissue
groups. The variation in ratio was not dependent on the
type of tissue, on the RNA extraction or on the total yield
of the RNA. In this laboratory we also found a much lower
proportion of miRNA, ranging from 1–5%, in small RNA
extracted from commonly used breast cancer cell lines
such as MCF-7, SK-BR-3, T47D and ZR-75-1 (data not
shown). A suitable EC gene will have to reflect such
changes in the global miRNA population. The variation in
miRNA yields and ratios may reflect genomic alterations,
common in cancer (reviewed in [52]. It has been shown
previously that miRNA frequently map to such regions of
instability [53]. This finding raises concerns over how
much of the small RNA used for cDNA reactions and other
applications is actually the RNA species of interest, and
this is especially relevant in studies employing non-
miRNA ECs.
Normfinder and geNorm were used to identify suitable
ECs for the relative quantitation of miRNA in fresh-frozen
primary breast tissue. There was no effect of tissue group
on scaled EC expression (P > 0.05, Fig. 1). As previously
stated [21] this is an important validation prior to use of
geNorm and NormFinder as these models assume candi-
dates are not differentially expressed between experimen-
tal groups. The absence of a significant difference in EC
expression between groups does not necessarily equate to
equivalent expression. Equivalence of expression was
assessed using the equivalence test [41]. Equivalent
expression between the independent tumour and normal
breast tissues was confirmed for all ECs using a fold
change cut-off of 3. Equivalent expression between the
malignant and benign tumour groups was also assessed
and was confirmed for all ECs with the exception of Z30
using the same cut-off. Using the benign, MF, BM and
VBM subgroups, NormFinder calculated the intra- and
intergroup variations and identified let-7a as the single
most stable EC with a stability value of 0.312. However,
the use of more than one EC is believed to increase the
accuracy of quantitation compared to the use of a single
EC [30,54,55] and use of let-7a alone would therefore not
be recommended. The EC gene pair, let-7a and RNU48
had an improved NormFinder stability value of 0.221.
GeNorm generates a gene-stability measure (M) which
may be defined as the average pairwise variation (V) for
one candidate EC gene compared to all other candidate
EC genes. Stepwise exclusion of the gene with the highest
M value results in recalculation of M values for the
remaining genes and ultimately, the identification of the
most stable pair [30]. The wide range in M values depicts
the high variability detected in candidate EC gene stability
(Table 2). The differences in miR-30* expression detected
between the tissue groups varied greatly depending on
which single EC was used for normalisation. For example,
in the BEN and BM breast tissues, the expression of miR-
30* could be made to appear up- or down-regulated rela-
tive to normal breast tissue depending on the EC gene
used (Fig. 2A). These results draw particular attention to
the potential effect of EC choice on the outcome of a study
and demonstrates the need for validation of candidate
ECs to produce reliable expression data. In geNorm, a nor-
malisation factor (NF) is generated for each sample using
the geometric average of the expression of the most stable
EC genes. The pairwise variation value, V is the variation
between two sequential NFs (Vn/n+1, where n = the
number of ECs used). The recommended pairwise varia-
tion of 0.15 is a guideline value and is not intended as an
absolute cut-off. This guideline value may not always be
GeNorm analysis of candidate ECs Figure 2
GeNorm analysis of candidate ECs. (A) Average 
expression stability of the EC candidates as calculated using 
GeNorm. A stability value (M) was calculated for each candi-
date EC. The least stable gene with the highest M value was 
automatically excluded and M values recalculated for the 
remaining ECs, ultimately resulting in a stability value for the 
two most stable ECs. (B) Determination of the optimal 
number of ECs for normalisation. The V value defines the 
pairwise variation between two sequential normalisation fac-
tors. GeNorm indicated optimal normalisation of gene 
expression could be achieved using the top five most stable 
ECs.
A
BBMC Molecular Biology 2008, 9:76 http://www.biomedcentral.com/1471-2199/9/76
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achievable [56] but should be considered, particularly if
small expression differences are to be measured. The low-
est pairwise variation value was achieved when the top 5
candidate genes were used as ECs (0.220, Fig. 3B). Let-7a
and miR-16 were identified as the most stable pair of EC
genes using geNorm. Significant differences in miR-30*
expression were detected between the tissue groups using
either the top two ECs (P = 0.01) or the top five ECs (P =
0.002, Fig. 2B). The post-hoc analyses revealed both nor-
malisation approaches detected significant differences
between the BM vs MF groups, the BM vs VBM groups and
the BEN vs VBM groups but each approach detected an
additional intergroup difference not detected by the other
approach. The number of genes to use in a normalisation
strategy is in most cases, a trade off between required res-
olution and practicality and for most purposes the EC
gene combination let-7a and miR-16 should suffice. Both
genes had the lowest stability values, as determined by
geNorm and NormFinder (Table 2).
A tumour suppressor role for let-7a in lung tissues seems
likely due to its widespread downregulation in tumour
versus normal lung tissues as well as the identification of
an oncogenic target, RAS, in this tissue [57]. However, it is
unclear whether let-7a is implicated in breast cancer since
the results of recent studies have been equivocal [57].
Whilst deletion of the miR-16 gene has been implicated in
the development of chronic lymphocytic leukemia [7], a
specific role for this miRNA in breast cancer has not been
identified. From a panel of 345 miRNAs, miR-16 was
selected in the top 15 most stably-expressed miRNAs
across 40 normal human tissue types [58]. A microarray
study [51] which looked at the expression of 287 miRNAs
in various normal and tumour tissues, not including
breast tissue, selected a panel of suitable EC genes based
on a number of criteria including high and consistent
expression of the miRNA across the tissues. Depending on
the tissue sample set, both let-7a and miR-16 were ranked
in the top 10–15 most stably-expressed miRNAs, support-
ing the findings of the present study.
The tissues used in this study are clinically and pathologi-
cally diverse (see Table 3) making this study of interest to
a broad spectrum of the breast cancer research commu-
nity. Recent findings would suggest that, unlike mRNAs,
the miRNA fraction present in FFPE tissues is relatively
unaffected by the fixation process and that miRNAs
extracted from these tissues may be accurately profiled
using RQ-PCR [27]. Thus, the ECs identified in this study
may also prove useful for miRNA RQ-PCR analysis of
FFPE breast tissues.
Conclusion
MiRNA expression studies utilising RQ-PCR should begin
with the careful selection of appropriate ECs for normali-
sation to ensure accurate quantitation of this very exciting
class of molecules. This study indicates an appropriate
strategy to validate ECs for any miRNA RQ-PCR study and
has identified a reliable two-gene normaliser for use in
breast cancer studies. We recommend the combined use
of Let-7a and miR-16 in this context.
Methods
Tissue Cohort
Primary breast tumour tissues (n = 31) were obtained
from patients during primary curative resection, at Galway
Boxplot of miR-30* relative quantities in benign (BEN, clear),  bone metastases (BM, dark), metastases free (MF, dashed)  and visceral and bone metastases (VBM, shaded) tissues using  different normalisation strategies Figure 3
Boxplot of miR-30* relative quantities in benign (BEN, clear), 
bone metastases (BM, dark), metastases free (MF, dashed) 
and visceral and bone metastases (VBM, shaded) tissues using 
different normalisation strategies. (Q. rel = E -ΔΔCt). The 
boxes represent the interquartile range. The line drawn 
through the boxes represents the median. Whiskers extend 
to the highest and lowest values in the data set. (A) miR-30* 
normalised using each EC individually. MiR-30* expression 
was significantly different between the tissue subgroups (P < 
0.05) except when using miR-26b as a single EC. (B) miR-30* 
normalised using geNorm's top two recommended ECs (2 × 
ECs = let-7a and miR-16) and geNorm's top five recom-
mended ECs (5 × ECs = let-7a, miR-16, miR-26b, miR-21 and 
RNU48). miR-30* was differentially expressed between 
groups using either the top 2 or the top 5 most stable ECs (p 
< 0.05). A significant difference was detected between the 
MF and VBM groups using the 5 EC gene approach, this was 
not detected when using the top 2 ECs for normalization.
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University Hospital, Galway, Ireland. Samples were cate-
gorised into benign (n = 5) or malignant groups (n = 26)
according to standard histopathological parameters. The
malignant breast tumour tissues were divided into three
groups depending on the patient's disease progression in
the five years following removal of the primary tumour;
tumours from patients who did not develop metastases
(metastases-free, MF, n = 13), those from patients who
developed bone metastases (BM, n = 7) and those from
patients who developed visceral and bone metastases
(VBM, n = 6).
Clinical data relating to the malignant tumour tissues
used in this study are shown in Table 3. RNA from normal
tissues (n = 5), recovered from patients undergoing reduc-
tion mastopexy surgery were used as calibrator samples
for RQ-PCR analysis. Tissues were immediately snap-fro-
zen in liquid nitrogen and stored at -80°C until RNA
extraction. Prior written and informed consent was
obtained from each patient and the study was approved
by the ethics review board of Galway University Hospital.
Clinical data were obtained from the Breast Cancer Data-
base at the Department of Surgery, Galway University
Hospital.
RNA Extraction
Approximately 100 mg of tissue was homogenised in 1–2
mL QIAzol (Qiagen, Crawley, UK) using a bench-top
homogeniser (Polytron PT1600E, Kinematica AG, Littau-
Luzem, Switzerland. Large (> 200 nt) and small RNA (<
200 nt) fractions were isolated separately using the RNe-
asy® Plus Mini Kit and RNeasy MinElute® Cleanup Kit
(Qiagen, West Sussex, UK) according to the Supplemen-
tary Protocol: Purification of miRNA from animal cells. A
portion of the purified large and small RNA was aliquot-
ted for quantitative and qualitative analysis using
NanoDrop1000® spectrophotometry and the Agilent 2100
Bioanalyzer respectively. The remaining RNA was stored
at -80°C until further use.
RNA Analysis
MicroRNA concentration and purity were assessed using
the NanoDrop1000®  spectrophotometer (NanoDrop
Technologies Inc, Wilmington, DE, USA). The small-RNA
enriched fraction was analysed using the Small RNA Assay
with the Agilent 2100 Bioanalyzer (Fig. 4) (Agilent Tech-
nologies, Palo Alto, CA, USA). For this assay, samples
were diluted to 1 ng/μL, within the quantitative and qual-
itative range of the assay. Integrity of the large RNA frac-
tion (> 200 nt) was assessed using the RNA 6000 Nano
Results of Agilent Bioanalyser Small RNA assay Figure 4
Results of Agilent Bioanalyser Small RNA assay. (A) Virtual gel-numbered samples refer to malignant breast tissues (as 
per Table 2), L = Ladder, N = Normal breast tissue, BEN = benign breast tissue. The lower marker is visible at 4 nt. Samples 
with a large percentage (> 75%) of miRNA (10–35 nt) include the samples BEN1, 19 and 25, the latter two belonging to the 
bone metastases (BM) patient group. The high intensity band in samples 9, 15, 17, 20, BEN1 and BEN2 between 60 and 80 nt 
represents high recovery of tRNA (73–93 nt). In general, these samples had a lower percentage of miRNA. (B) Electrophero-
gram. Numbered samples refer to malignant breast tissues (as per Table 2), BEN = benign breast tissue.
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LabChip Series II Assay (Agilent Technologies). An RNA
integrity number (RIN) is generated for each sample
based on the ratio of ribosomal bands and also the pres-
ence or absence of degradation products on the electro-
phoretic image. A threshold value of RIN ≥ 7 was applied.
Candidate Endogenous Control Genes
The small nuclear and small nucleolar genes were chosen
from the ten Human TaqMan MicroRNA Assay Controls
available from Applied Biosystems (Foster city, CA, USA)
at the time of study. The five miRNA genes were selected
based on their known expression in breast cancer tissues
and/or based on their previous use as an EC gene in a
breast cancer study [24]. Known functions of the candi-
dates are listed in Table 4.
cDNA Synthesis and RQ-PCR
Each reaction was primed using a gene-specific stem-loop
primer. The primer and probe sequences for let-7a, miR-
10b, miR-16, miR-26b and miR-30* were as previously
published [18]. Where sequences were available, primers
were obtained from MWG Biotech (Ebersberg, Germany).
Otherwise, assays containing the RT stem-loop primer
and the PCR primers and probes were used (Applied Bio-
systems, Foster City, CA, USA). Small RNA (5 ng) was
transcribed using MultiScribe Reverse Transcriptase
(Applied Biosystems). The reaction was performed using
a GeneAmp PCR system 9700 thermal cycler (Applied
Biosystems). An RT-negative control was included in each
batch of reactions. The PCR reactions were carried out in
a final volume of 20 μL using an ABI Prism 7000 Sequence
Detection System (Applied Biosystems). Briefly, reactions
consisted of 1.33 μL cDNA, 1× TaqMan Universal PCR
Master mix, No AmpErase UNG, 0.2 μM TaqMan® Probe
(Applied Biosystems), 1.5 μM forward primer and 0.7 μM
reverse primer. The PCR reactions were initiated with a 10
min incubation at 95°C followed by 40 cycles of 95°C for
15 sec and 60°C for 60 sec. cDNA, synthesised from
pooled normal breast tissue, was included on each 96-
well plate as an interassay control and calibrator. All reac-
tions were performed in triplicate. The threshold standard
deviation for intra- and inter-assay replicates was 0.3. PCR
amplification efficiencies were calculated for each candi-
date EC RQ-PCR assay using the formula E = (10-1/slope-1)
× 100, using the slope of the plot, Ct versus log input of
cDNA. PCR amplification efficiencies for each EC candi-
date are shown in Table 4.
Data Analysis
Relative quantities (Q.rel) for each candidate EC gene
were calculated from cycle threshold (Ct) values scaled to
a calibrator sample (pool of 5 normal tissues) and cor-
rected for efficiency of amplification (E) according to the
formula: Q.rel. = E-ΔCt, with ΔCt = average Ct test sample-
average Ct calibrator sample. To calculate the expression
of the target gene miR-30* relative to each of the EC can-
didates, the ΔΔCt method was used, with ΔΔCt = (Ct target
gene, test sample-Ct endogenous control gene, test sam-
ple)-(Ct target gene, calibrator sample-Ct endogenous
control gene, calibrator sample). Again, quantities were
corrected for efficiency of amplification and the errors
were calculated as previously described [30].
Stability of EC expression was analysed using two freely-
available programmes; geNorm and NormFinder.
GeNorm (vs. 3.4) is a Visual Basic Application for Excel
that calculates a gene-stability measure (M) for all candi-
date EC genes in a given set of samples and determines the
most reliable pair of ECs, showing greatest stability of
expression ratio across samples. It is based on a pair-wise
comparison model. NormFinder [54], an excel-add-in,
uses an ANOVA-based model to estimate intra- and inter-
group variation. It combines these estimates to produce a
stability value for each candidate. NormFinder indicates
the single most stable EC and EC pair where the stability
of the latter is greater than that of the single EC. Prior to
geNorm and NormFinder analysis, Ct values were con-
verted into Q.rel values (E = -ΔCt), as detailed above. For
Normfinder analysis samples were grouped into metas-
tases free (MF, n = 13), bone metastases (BM, n = 7), vis-
Table 4: Details of candidate endogenous control (EC) genes and their PCR amplification efficiencies
Name Mature
length
(nt)
RNA
species
Accession
number
Function Reference PCR
Amplification
efficiency (%)
let-7a 22 miRNA MI0000060* Negatively regulates RAS oncogene [57] 96.3
miR-10b 22 miRNA MI0000267 * No functionally-verified targets 104.1
miR-16 22 miRNA MI0000070 * Negatively regulates B-cell lymphoma mRNA in chronic 
lymphocytic leukaemia patients
[7] 104.3
miR-21 22 miRNA MI0000077 * Antiapoptotic, negatively regulates apoptosis-related genes [42] 96.8
miR-26b 22 miRNA MI0000084 * No functionally-verified targets 98.1
RNU19 198 snoRNA X94290 ** May be involved in pre-rRNA processing [59-61] 99.2
RNU48 63 snoRNA NR_002745 ** Guides the 2'O-ribose methylation of 28S rRNA [62] 108.9
Z30 97 snoRNA AJ007733 ** Guides the methylation of the Am47 residue in U6 snRNA [63] 104.1
*mirBase database accession number ** Entrez gene IDBMC Molecular Biology 2008, 9:76 http://www.biomedcentral.com/1471-2199/9/76
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ceral and bone metastases (VBM, n = 6) and benign (BEN,
n = 5) as described above. Statistical analyses were per-
formed using Minitab (vs 15; Minitab Ltd., Coventry,
UK). Distribution of data was determined using the
Anderson-Darling normality test and parametric tests
were used where appropriate. Levene's statistic was used
to assess if there was a significant difference in variance
between genes. The equivalence test was used to assess
whether genes were equivalently expressed between
tumour (benign and malignant) and normal breast tissues
and between malignant and benign breast tissues [41].
ANOVA, Fisher's least significant difference tests and
Kruskal Wallis tests were applied to determine the effect of
EC on target gene expression. P values < 0.05 were consid-
ered statistically significant.
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